TiNivo-2
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
- NCT04987203 ↗
- Completed
- AVEO Pharmaceuticals, Inc.
- Deep
We haven't built an HCP commentary report on TiNivo-2 (tivozanib and nivolumab in Renal Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses TiNivo-2’s comparison of tivozanib plus nivolumab with tivozanib alone after prior immune-checkpoint inhibitor therapy, including trial design and treatment sequencing in metastatic renal cell carcinoma. Discussion covers whether the trial clarifies a possible distinction between PD-1 and PD-L1 rechallenge raised in relation to CONTACT-03, and the broader role of checkpoint blockade after progression. Speakers also discuss tivozanib dosing, side-effect profile, patient-reported outcomes, and whether further research on pembrolizumab rechallenge is warranted.
Indexed commentary on TiNivo-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 102 | |
| YouTube | 62 | |
| Podcasts | 30 | |
| X videos | 3 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- Tivozanib; Nivolumab
- Arms
- Tivozanib in Combination with Nivolumab · Experimental
- Tivozanib · Experimental
- Enrollment
- 343
- Primary outcomes
- Progression free survival
- Sponsor
- AVEO Pharmaceuticals, Inc. with Parexel, Bristol-Myers Squibb
- Start
- Sep 9, 2021
- Primary completion
- Jan 20, 2026
- Results posted
- No
- Registry record
- NCT04987203 · updated May 8, 2026
Publications
linked from the registry- Choueiri TK, Albiges L, Barthelemy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet. 2024 Oct 5;404(10460):1309-1320. doi: 10.1016/S0140-6736(24)01758-6. Epub 2024 Sep 13. PubMed 39284329
- Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18. PubMed 35304832